A rare cause of heart failure
DOI:
https://doi.org/10.24950/rspmi.990Keywords:
amyloidosis, cardiomyopathy, heart failureAbstract
The authors describe the case of a previously asymptomatic
48-year-old patient, evolving for a month with a condition of
fatigue, exertional dyspnea and lower limb edema. An echocardiogram revealed concentric left ventricular hypertrophy, compromised systolic function and a restrictive pattern of left ventricular
filling, resulting in her admission to the Cardiology Ward for clinical
stabilization and assessment of her heart failure etiology. The
patient was submitted to various diagnostic procedures including
a cardiac magnetic resonance and renal and abdominal fat pad
biopsies, leading to a diagnosis of primary systemic amyloidosis
with cardiac and renal involvement. We conclude with a brief
summary of this uncommon clinical entity usually presenting a
very poor prognosis
Downloads
References
Bellotti V, Nuvolone M, Giorgetti S et al. The workings of the amyloid diseases. Ann Med 2007; 39:200.
Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010; 17:101
Nyirady J, Schwartz R. Primary Systemic Amyloidosis, Emedicine, updated 2009 April 29. Available from: http./www.emedicine.medscape.com
Gillmore JD, Hawkins PN. Drug Insight: Emerging therapies for amyloidosis. Nature Clinical Practice Nefrology 2006; 2(5): 263-270.
Hess O, Mckenna W, Schulteiss HP. Myocardial Disease. In Camm A, Liescher T, Serruys P. The ESC Textbook of Cardiovascular Medicine. 2nd edition. Oxford: Oxford University Press 2009: 668-690.
Klein AL, Hatle LK, Burstow DJ et al. Doppler characterization of left ventricular diastolic functions in cardiac amyloidosis, J Am Coll Cardiol 1989;13: 1017-1026.
Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy, J Am Coll Cardiol, 2008, 51:1022-1030.
Gameren II, Vellenga E, Hazenberg B. Novel treatments for systemic amyloidosis, Int J Clin Rheum. 2009, 4(2):171-188.
Melmed GM, Fenves AZ, Stone MJ. Urinary findings in renal light chain-derived amyloidosis and light chain disease, Clin Lymphoma Myeloma. 2009; 9(3).
Rajkumar SV, Gertz MA. Advances in the treatment of amyloidosis, N Eng J Med 2007; 356:2413-2415.
Palladini G et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone and thalidomide, Ann Hematol2009; 88: 347-350.
Petrie CJ, MacDonald M, Lindsay MM. Neurocardiogenic syncope precipitated by digoxin, Scottish Medical Journal 2007; 52(4): 54.
Parikh S, Lemos J. Current therapeutic strategies in cardiac amyloidosis, Current Treatment Options in Cardiovascular Medicine 2005; 7(6): 443-448.
Halwani O, Delgado D. Cardiac amyloidosis: An approach to diagnosis and management, Expert Rev Cardiovasc Ther. 2010;8(7): 1007-1113
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
